Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * Lehoux Lawrence	2. Date of Event Requiring Statement (MM/DD/YYYY) 7/9/2021	3. Issuer Name and Ticker or Trading Symbol CEN BIOTECH INC [CENBF]
(Last)        (First)        (Middle) 300-3295 QUALITY WAY	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director                          _____ 10% Owner ___X___ Officer (give title below)        _____ Other (specify below) Chief Technology Officer /
(Street) WINDSOR, ONTARIO, CANADA, A6 N8T 3R9       (City)              (State)              (Zip)	5. If Amendment, Date Original Filed(MM/DD/YYYY)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	3030000 (1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:
(1)	Lawrence Lehoux (the "Reporting Person") was appointed to his positions with CEN Biotech, Inc. (the "Issuer") on July 9, 2021 and owned 3,030,000 shares of the Issuer's common stock at such date.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Lehoux Lawrence 300-3295 QUALITY WAY WINDSOR, ONTARIO, CANADA, A6 N8T 3R9	X		Chief Technology Officer

Signatures
/s/ Lawrence Lehoux		7/21/2021
**Signature of Reporting Person		Date